By Paul Raeburn
Off-label promotion has long been considered a serious white-collar crime. The FDA has fined drug companies billions of dollars for off-label violations. The aim: to prevent them from overstating the benefits and understating the risks of their products, a practice known as misbranding – and one that sometimes leads to patients getting drugs that prove harmful or even deadly.
The post First Amendment claims seen as Rx for drug makers, headache for consumers appeared first on Florida Bulldog.